DIROXIMEL FUMARATE Drug Patent Profile

Which patents cover Diroximel Fumarate, and when can generic versions of Diroximel Fumarate launch?

Diroximel Fumarate is a drug marketed by Zydus and is included in one NDA.

The generic ingredient in DIROXIMEL FUMARATE is diroximel fumarate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the diroximel fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Diroximel Fumarate

A generic version of DIROXIMEL FUMARATE was approved as diroximel fumarate by ZYDUS on November 12^th, 2025.

Summary for DIROXIMEL FUMARATE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	48
Clinical Trials:	8
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DIROXIMEL FUMARATE
DailyMed Link:	DIROXIMEL FUMARATE at DailyMed

Recent Clinical Trials for DIROXIMEL FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Lille	PHASE2
Ministre de la Sant	PHASE2
Rosetrees Trust	NA

See all DIROXIMEL FUMARATE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for DIROXIMEL FUMARATE

L04AX	Other immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for DIROXIMEL FUMARATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VUMERITY	Delayed-release Capsules	diroximel fumarate	231 mg	211855	1	2020-12-23

US Patents and Regulatory Information for DIROXIMEL FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus	DIROXIMEL FUMARATE	diroximel fumarate	CAPSULE, DELAYED RELEASE;ORAL	218596-001	Nov 12, 2025	AB	RX	No	No

EU/EMA Drug Approvals for DIROXIMEL FUMARATE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Biogen Netherlands B.V.	Vumerity	diroximel fumarate	EMEA/H/C/005437Vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see Section 5.1 for important information on the populations for which efficacy has been established).	Authorised	no	no	no	2021-11-15

Market Dynamics and Financial Trajectory for DIROXIMEL FUMARATE

Last updated: February 20, 2026

What is the current landscape of DIROXIMEL FUMARATE?

Diroximel Fumarate (DRF) is an oral fumarate used for treating relapsing forms of multiple sclerosis (MS). Marketed as Vumerity (by Biogen), it received FDA approval in October 2019 as an alternative to dimethyl fumarate (Tecfidera). Its formulation claims to reduce gastrointestinal side effects associated with Tecfidera.

Current market status shows moderate adoption, driven by a need for improved tolerability. It competes primarily with Tecfidera, which holds a dominant position in MS therapies with a global revenue exceeding $3 billion annually.

How does the market for Diroximel Fumarate compare to other MS therapies?

Product	Approval Year	Indication	Market Position	Estimated Global Revenue (2022)	Notes
Tecfidera (Dimethyl Fumarate)	2013	Relapsing MS	Market leader	~$3.3 billion[1]	First fumarate approved; broad prescriber base
Vumerity (Diroximel Fumarate)	2019	Relapsing MS	Niche but growing	Estimated ~$0.2 billion[2]	Better GI tolerability; newer entrant
Other MS drugs	Varies	Various MS forms	Niche competitors	Varies	Ocrelizumab, Mavenclad, Aubagio

Diroximel Fumarate’s adoption remains limited by its later market entry and the established base of Tecfidera users. Its growth potential hinges on superior tolerability and physician preference shifts.

What are the key drivers influencing Diroximel Fumarate’s market performance?

Regulatory and clinical factors

• Approval and label extension: Approved in 2019 for relapsing MS.
• Efficacy: Demonstrates similar efficacy to Tecfidera in reducing relapse rates but with less gastrointestinal discomfort.
• Side effect profile: Significantly fewer GI adverse events, which is a crucial factor in treatment adherence.

Competitive dynamics

• Brand loyalty and prescriber inertia: Tecfidera’s established presence creates barriers for Diroximel Fumarate penetration.
• Pricing strategies: Biogen set a list price comparable to Tecfidera, around $80,000 annually. Discounting occurs but is limited by insurance negotiations.

Market access and reimbursement

• Insurance coverage: Has established formulary access in several major markets.
• Patient preference: Driven by tolerability benefits, especially for patients who experience side effects with Tecfidera.

Emerging factors

• New formulations and pipeline products: The introduction of biosimilars or new oral MS drugs could impact demand.
• Long-term safety data: Pending post-marketing studies may influence prescribing trends.

What are the financial projections for Diroximel Fumarate?

Revenue outlook

Based on current market penetration estimates and the MS drug market’s growth rate:

Year	Estimated Global Revenue	Assumptions
2023	~$250 million	8% market share of fumarates, slow penetration
2025	~$400 million	Increased adoption due to tolerability advantages
2030	~$700 million	Market share stabilizes at approximately 15%, expanded indications (if approved)

Revenue growth drivers

• Launch of additional formulations or combination products.
• Expansion into emerging markets with increasing MS diagnosis rates.
• Growth in overall MS drug market, projected at CAGR ~5% through 2030.

Risks to financial trajectory

• Delay or failure of post-market safety data to confirm long-term safety.
• Competitive entry of biosimilars or alternative oral therapies.
• Changes in healthcare reimbursement policies affecting drug prices.

How does the pipeline landscape impact Diroximel Fumarate's prospects?

Diroximel Fumarate currently lacks a significant pipeline competition from within Biogen. However, the broader MS pipeline includes drugs such as:

• Ozanimod (by Bristol-Myers Squibb): Approved in 2020, with a similar efficacy and a different side effect profile.
• Siponimod (by Novartis): Approved for secondary progressive MS.
• New oral agents with improved efficacy or safety profiles could erode Diroximel Fumarate’s market share.

Summary of key market factors

• Diroximel Fumarate gains favor through a better side effect profile.
• It remains secondary to Tecfidera in market share but shows promising growth potential.
• Long-term growth depends on regulatory support, safety data, and competitive strategies.
• Market size is limited by the overall MS therapeutics market and physician preferences.

Key Takeaways

• Diroximel Fumarate has a niche position within MS treatments; its success relies heavily on tolerability.
• Revenue is expected to grow gradually, reaching approximately $700 million globally by 2030 if market and safety considerations remain positive.
• Competitive pressures from newer oral agents and biosimilars could constrain long-term growth.
• Market access and insurance coverage are critical for expansion.

FAQs

1. What distinguishes Diroximel Fumarate from Tecfidera?

   • It offers similar efficacy with fewer gastrointestinal side effects.

2. What is its current market share in MS therapies?

   • Estimated at around 2-3%, with growth prospects contingent on tolerability benefits.

3. How is pricing comparable to Tecfidera's?

   • List price around $80,000 annually, with limited discounts.

4. Which markets are critical for growth?

   • The U.S., Europe, and emerging markets with rising MS prevalence.

5. What are the significant hurdles for Diroximel Fumarate’s expansion?

   • Long-term safety data, prescriber loyalty to Tecfidera, and competition from newer drugs.

References

[1] IQVIA. (2022). Global MS Market Data. IQVIA Reports.

[2] Biogen. (2019). Vumerity FDA approval announcement. FDA.gov.

[3] Evaluate Pharma. (2022). MS drug market analysis. Evaluation Reports.